New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Abstract In 2013, the European Heart Rhythm Association (EHRA) published a Practical
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these …

Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be
considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …